ASSOCIATION OF THE PRO72ARG (RS1042522) POLYMORPHISM OF THE TP53 GENE WITH THE DEVELOPMENT OF MYELOPROLIFERA-TIVE NEOPLASMS IN THE KHOREZM REGION

FULL TEXT:

Abstract

Objective: To evaluate the impact of allele and genotype variants of the Pro72Arg (rs1042522) polymorphism of the TP53 gene on the development of myeloproliferative neoplasms (MPNs). Materials and methods: The study involved 110 patients with clinically and genetically confirmed cases of Рh-positive and Рh-negative MPNs, examining the role of the Pro72Arg (rs1042522) polymorphism of the TP53 gene in the development and prognosis of MPNs. Among them, 34 patients (CML – 26, IP – 7, IT-1) resided in ecologically unfavorable regions of the Khorezm region near the Aral Sea (Group I), and 76 patients (CML – 40, IP – 24, IT – 10, PMF – 2) lived in relatively favorable areas within the Khorezm region (Group II). DNA samples from 105 unrelated healthy individuals of Uzbek ethnicity were used as controls. Results: The results showed that the Pro allele is associated with an increased likelihood of developing diseases, while the high frequency of the Arg allele in the control group suggests a protective effect (χ² = 12.4; p = 0.01). The Pro/Pro genotype was significantly common in patients from unfavorable regions of Xorezm region (χ2=5.6; p=0.03; RR=3.6; 95%CI: 1.05-12.38;), statistical indicators of this genotype indicate its potential association with an increased risk of the disease, the presence of which increases the risk of developing MPN by more than 4 times (OR=4.2; 95%CI:1.27-13.57); whereas the Pro/Arg genotype (χ² = 5.9; p = 0.03) was significantly associated with an increased risk of disease, raising the risk of developing MPNs by more than 2 times (OR = 2.1; 95% CI: 1.15-3.77). The Arg/Arg genotype (χ² = 11.1; p = 0.01), on the other hand, was associated with a protective effect, with its high frequency in the control group confirming its role as a factor that reduces the risk of disease.

About the Authors

List of references

Schulz E, Sill H. The TP53 Pro72Arg SNP in de novo acute myeloid leukemia. Haematologica. 2017 May;102(5): e214-e215. doi: 10.3324/haematol.2017.165019. PMID: 28458254; PMCID: PMC5477628.

Mohammad Salman Akhtar, Raed A. Alharbi, Genetic association of TP53 Pro72Arg polymorphism (rs1042522) in Leukemia: An updated meta-analysis of 10 case-control studies, Human Gene, Volume 34, 2022, 201130, ISSN 2773-0441, https://doi.org/10.1016/j.humgen.2022.201130.

Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, Foran J, Palmer J, Badar T, Patnaik MM, Reichard KK, He R, Zepeda Mendoza CJ, Shah M, Orazi A, Arber DA, Pardanani A, Vannucchi AM, Hiwase D, Gangat N, Guglielmelli P. TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27609. Epub ahead of print. PMID: 39873146.

Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017 Jul 13;36(28):3943-3956. doi: 10.1038/onc.2016.502. Epub 2017 Mar 13. PMID: 28288132; PMCID: PMC5511239.

Xiang Zhou, Qian Hao, Hua Lu, Mutant p53 in cancer therapy—the barrier or the path, Journal of Molecular Cell Biology, Volume 11, Issue 4, April 2019, Pages 293–305, https://doi.org/10.1093/jmcb/mjy072

Yi K, Yang L, Lan Z, Xi M. The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis. Int J Gynecol Cancer. 2016 Jul;26(6):1121-8. doi: 10.1097/IGC.0000000000000725. PMID: 27327151.

Garde-García H, Redondo-González E, Maestro-de Las Casas M, Fernández-Pérez C, Moreno-Sierra J. Biomarkers and intermediate-high risk non-muscle invasive bladder cancer: a multivariate analysis of three different cellular pathways with pronostic implications. Clin Transl Oncol. 2021 Apr;23(4):840-845. doi: 10.1007/s12094-020-02476-7. Epub 2020 Aug 24. PMID: 32839927.

Roshani D, Abdolahi A, Rahmati S. Association of p53 codon 72 Arg>Pro polymorphism and risk of cancer in Iranian population: A systematic review and meta-analysis. Med J Islam Repub Iran. 2017 Dec 27;31:136. doi: 10.14196/mjiri.31.136. PMID: 29951436; PMCID: PMC6014797.

Saima Saleem, et al. P53 (Pro72Arg) polymorphism associated with the risk of oral squamous cell carcinoma in gutka, niswar and manpuri addicted patients of Pakistan, Oral Oncology, Volume 49, Issue 8, 2013, Pages 818-823, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2013.04.004.

Drokow EK, Chen Y, Waqas Ahmed HA, Oppong TB, Akpabla GS, Pei Y, Kumah MA, Neku EA, Sun K. The relationship between leukemia and TP53 gene codon Arg72Pro polymorphism: analysis in a multi-ethnic population. Future Oncol. 2020 May;16(14):923-937. doi: 10.2217/fon-2019-0792. Epub 2020 Apr 17. PMID: 32301350.

Diakite, B., Kassogue, Y., Dolo, G. et al. p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies. BMC Med Genet 21, 206 (2020). https://doi.org/10.1186/s12881-020-01133-8

Shen, CC., Cheng, WY., Lee, CH. et al. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer 20, 709 (2020). https://doi.org/10.1186/s12885-020-07210-8

Ahmed, S., Safwat, G., Moneer, M.M. et al. Prevalence of TP53 gene Pro72Arg (rs1042522) single nucleotide polymorphism among Egyptian breast cancer patients. Egypt J Med Hum Genet 24, 24 (2023). https://doi.org/10.1186/s43042-023-00405-1

How to Cite

1.
Zhumaboeva M, Boboev K, Matmurodov R, Zhumanazarova S. ASSOCIATION OF THE PRO72ARG (RS1042522) POLYMORPHISM OF THE TP53 GENE WITH THE DEVELOPMENT OF MYELOPROLIFERA-TIVE NEOPLASMS IN THE KHOREZM REGION. MSU [Internet]. 2025 Apr. 16 [cited 2025 Apr. 20];(2):74-9. Available from: https://fdoctors.uz/index.php/journal/article/view/122
Views: 3